Bispecific monoclonal antibodies: Application in experimental clinical oncology

Research output: Contribution to journalArticle


Many strategies for experimental immunotherapy of cancer attempt to amplify the use of tumor specific cytotoxic T lymphocytes (CTL). However tumor cells may escape recognition by CTL because of the heterogeneity of different molecules acting as restrition elements. One of the most promising approaches uses bispecific monoclonal antibodies (bsmAbs) which are able to focus on and activate human effector cells on the tumor site. Human resting peripheral NK, T cells or CTL clones derived from patients and targeted by appropriate bsmAbs to tumor cells expressing a tumor associated antigen, are efficient in lysing tumor cells and clones in vitro and in vivo. Moreover, tumor-bearing SCID mice which were treated by bsmAbs and human peripheral blood lymphocytes' had complete regressions of established tumors and most or all animals were cured by human NK-cell or Ttcell cytotoxicity, respectively. As CTL isolated from patients can be sufliciently activated by bsmAbs and are able to overcome the intratumor susceptibility to cell lysis, the clinical application of these reagents holds for becoming a rational approach because of the simplicity and efficiency in treating human malignancy. The encouraging results employing a bsmAb obtained in the treatment of ovarian cancer are deserving of the clinical evaluation of this new therapeutic approach.

Original languageEnglish
Pages (from-to)64-69
Number of pages6
JournalMinerva Biotecnologica
Issue number2
Publication statusPublished - 1996


  • Anti-tumor effector cells
  • Bispecific monoclonal antibodies
  • Tumor anti-gen
  • Tumor-cell lysis

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Applied Microbiology and Biotechnology

Fingerprint Dive into the research topics of 'Bispecific monoclonal antibodies: Application in experimental clinical oncology'. Together they form a unique fingerprint.

  • Cite this